• 1
    Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al, for the International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 3902.
  • 2
    Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13: 28998.
  • 3
    Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl 2006; 95: 3841.
  • 4
    Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 4216.
  • 5
    Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002; 20: 1213.
  • 6
    Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13–4 polymorphisms. Arthritis Rheum 2008; 58: 28926.
  • 7
    Ramanan AV, Schneider R. Macrophage activation syndrome: what's in a name! J Rheumatol 2003; 30: 25136.
  • 8
    Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al, for the MAS Study Group. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38: 7648.
  • 9
    Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 11338.
  • 10
    Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41: 142835.
  • 11
    Petty RE, Cassidy JT. Chronic arthritis. In: Petty RE, Cassidy JT, editors. Textbook of pediatric rheumatology. Philadelphia: WB Saunders Company; 2005. p. 206339.
  • 12
    Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tan AS, Roettcher PA, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010; 62: 599608.
  • 13
    Zeft A, Hollister R, LaFleur B, Prahalad S, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. Clin Exp Rheumatol 2009; 15: 1614.
  • 14
    Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 54555.
  • 15
    Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 9981006.
  • 16
    Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 9: 147986.
  • 17
    Irigoyen PI, Olson J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum 2004; 50 Suppl: S437.
  • 18
    Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al, for the Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 55767.
  • 19
    Quartier P, Allantz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 74754.
  • 20
    Weiss JE, Lee T, Rabinovich CE, Wallace CA, Oliveira SK, Onel K, et al. Life-threatening pulmonary hypertension (PH) and alveolar proteinosis (AP) in systemic JIA (sJIA) [abstract]. Arthritis Rheum 2008; 58 Suppl: S2578.
  • 21
    Prieur AM, Malleson PN, Kimura Y. Systemic arthritis. In: Ilona YK, Szer S, Malleson PN, Southwood TR, editors. Arthritis in children and adolescents: juvenile idiopathic arthritis. New York: Oxford University Press; 2006. p. 21022.
  • 22
    Schultz R, Mattila J, Gappa M, Verronen P. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA). Pediatr Pulmonol 2001; 32: 397402.
  • 23
    Mubashir E, Ahmed MM, Hayat S, Heldmann M, Berney SM. Pulmonary hypertension in a patient with adult-onset Stills disease. Clin Rheumatol 2007; 26: 135961.
  • 24
    Padeh S, Laxer RM, Silver MM, Silverman ED. Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum 1991; 34: 15759.
  • 25
    Van Hoeyweghen RJ, De Clerck LS, Van Offel JF, Stevens WJ. Interstitial lung disease and adult-onset Still's disease. Clin Rheumatol 1993; 12: 41821.
  • 26
    Zen A, Yamashita N, Ueda M, Asakawa Y, Yoshikawa Y, Funai T, et al. A case of adult Still's disease with pulmonary hypertension. Ryumachi 1990; 30: 4552. In Japanese.
  • 27
    Nolan PK, Daniels C, Long F, Dishop MK, Baker P, Guarin M, et al. Severe diffusion capacity reduction in a case of systemic onset juvenile rheumatoid arthritis with mild pulmonary hypertension [abstract]. Chest 2005; 128: 435S6S.
  • 28
    Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598604.
  • 29
    Leber A, Carette S, Chapman KR, Hwang DM, Singer LG, Marras TK. A 21-year-old man with systemic-onset juvenile rheumatoid arthritis, cough and progressive dyspnea. Can Respir J 2010; 17: e424.
  • 30
    Thakare M, Habibi S, Agrawal S, Narsimulu G. Pulmonary arterial hypertension complicating adult-onset Still's disease. Clin Rheumatol 2009. E-pub ahead of print.
  • 31
    Price LC, Wort SJ, Perros F, Dorfmuller P, Huertas A, Montani D, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141: 21021.
  • 32
    Hall S, Brogan P, Haworth SG, Klein N. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax 2009; 64: 77883.
  • 33
    Pinto RF, Higuchi Mde L, Aiello VD. Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. Cardiovasc Pathol 2004; 13: 26875.
  • 34
    Gonzalez-Rothi RJ, Harris JO. Pulmonary alveolar proteinosis: further evaluation of abnormal alveolar macrophages. Chest 1986; 90: 65661.
  • 35
    Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 12118.
  • 36
    Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 162831.
  • 37
    Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 9207.
  • 38
    Dorfmuller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 5349.
  • 39
    Abramowicz MJ, Van Haecke P, Demedts M, Delcroix M. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 2003; 22: 5602.
  • 40
    Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 73744.
  • 41
    Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118: 23729.
  • 42
    De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile chronic arthritis. Arthritis Rheum 1991; 34: 115863.
  • 43
    Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodani M. Study of IL-2, IL-6, TNF-α, IF-gamma and delta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994; 12: 5615.
  • 44
    Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998; 10: 72934.
  • 45
    Pascual V, Allantaz F, Arce E, Stichweh D, Connolly J, Punaro M, et al. Dramatic clinical response to IL-1 blockade in systemic onset juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2004; 50: L14.
  • 46
    Verbsky JW, White AJ. Effective use of the recombinant interleukin-1 receptor agonist anakinra in therapy resistant systemic onset jevenile rheumatoid arthritis. J Rheumatol 2004; 31: 20715.
  • 47
    Henrickson M. Efficacy of anakinra in refractory systemic arthritis [abstract]. Arthritis Rheum 2004; 50 Suppl: S438.
  • 48
    Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single ascending doses of MRA in caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7: R12818.
  • 49
    De Benedetti F, Brunner F, Ruperto H, Calvo N, Cuttica I, Malattia R, et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER Trial [abstract]. Arthritis Rheum 2010; 62 Suppl: S5967.
  • 50
    Dewitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al, on behalf of the Juvenile Idiopathic Arthritis Disease -Specific Research Committee of the Childhood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012; 64: 100110.
  • 51
    Smith MY, Sobel RE, Wallace CA. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res (Hoboken) 2010; 62: 8004.